Dr. Kausche is a seasoned executive with over 25 years’ experience in the animal and consumer health industries. Most recently, he was SVP, Global Head of R&D for Boehringer Ingelheim Animal Health from 2017 to 2018. Between 2008 and 2016, he led the global R&D organizations for Novartis Animal Health, Novartis Consumer Health, and Merial. He previously spent two years as VP, US Sales for Novartis Animal Health and started his career in R&D at The Upjohn Company, Pharmacia and Pfizer Animal Health.
Dr Mark Heffernan, CEO of Stonehaven Incubate, said: “We are very grateful to our Co-founder and outgoing Chairman, Matthias Hofer, who has helped lead us building up Stonehaven Incubate to the point it is now. Matthias will remain as an active board member.
“We are also delighted that Fabian has accepted the role as we look to further develop and grow. He brings a huge amount of experience and variety of skills which will be of significant benefit to us and the businesses with which we collaborate. He’s joining at an exciting time with several new opportunities being evaluated and coming to fruition during 2019.”
Matthias Hofer added: “We are very happy to welcome Fabian to the team. Stonehaven is the only dedicated, animal health group committed to creating new companies de novo from disruptive human technology. His vast wealth of experience can really help us to deliver our mission to bring human innovations to animal health.”
Dr. Kausche received his veterinary degree and Dr.med.vet from Hanover Veterinary School in Germany and a Master of Science in animal disease modeling from Iowa State University. Having completed the Advanced Management Program in 2005, he is also an alumnus of Harvard Business School. In March, Dr. Kausche was appointed chairman of PetMedix Ltd, a company focused on the research and development of novel monoclonal antibodies for companion animals.
June 18, 2019 - Stonehaven Incubate